Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.3%

6 terminated out of 53 trials

Success Rate

79.3%

-7.2% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

35%

8 of 23 completed with results

Key Signals

8 with results79% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (11)
Early P 1 (1)
P 1 (16)
P 2 (13)

Trial Status

Completed23
Recruiting12
Unknown7
Terminated6
Active Not Recruiting3
Not Yet Recruiting1

Trial Success Rate

79.3%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (53)

Showing 20 of 20 trials
NCT02315612Phase 1Completed

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

NCT05550948Not ApplicableActive Not RecruitingPrimary

Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer

NCT06047886Phase 1Recruiting

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

NCT07516353Not ApplicableNot Yet Recruiting

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

NCT04644016Phase 2Recruiting

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

NCT06131801Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT02990572RecruitingPrimary

Amish/Mennonite Research Contact Registry

NCT05016947Phase 1Active Not Recruiting

Venetoclax Plus Inotuzumab for B-ALL

NCT03571321Phase 1Recruiting

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT07252336Phase 2RecruitingPrimary

A Multicenter Study of CAR-T Cells in Primary Ph+All

NCT05940961Phase 2RecruitingPrimary

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

NCT06244147CompletedPrimary

Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults

NCT00776373Phase 1TerminatedPrimary

Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

NCT06976736Recruiting

A Long Term Follow-up Study of TScan TCR-T Products

NCT04473911Phase 1Completed

Haplo Peripheral Blood Sct In GVHD Prevention

NCT03739502Phase 2Recruiting

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

NCT01532635Phase 2Terminated

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT03114553CompletedPrimary

Family History in a Singaporean Healthy Population

NCT05476770Phase 1Recruiting

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT03154346Active Not RecruitingPrimary

Project Baseline Health Study

Scroll to load more

Research Network

Activity Timeline